ai-for-biotech
(2)
Form Bio
Form Bio is an Austin-based computational life sciences company that builds AI-driven software to speed up the design, characterization, and manufacturing of genetic medicines, especially adeno-associated virus (AAV) cell and gene therapies. Spun out of Colossal Biosciences in 2022 with a $30M Series A, its platform lets scientists model billions of therapeutic vector designs in silico to improve efficacy, safety, and manufacturability before ever entering the lab, targeting the manufacturing bottleneck that drives the majority of FDA rejections in the field.
Ann Lin
Ann Lin is the co-founder and CEO of Cromatic, an AI-native RevOps platform that helps life-science companies find and manage contract research organizations (CROs). A Stanford genetics PhD and Forbes 30 Under 30 (Science, 2020) honoree, she made her name in the lab of Jason Sheltzer at Cold Spring Harbor, where her team showed that a celebrated cancer drug did not hit its supposed target. After scientifically co-founding the drug-discovery startup Meliora Therapeutics, she turned a Google Sheet of outsourcing complaints into a company, raising a $5.3M seed round in 2023 to fix the notoriously opaque market for biotech R&D vendors.